288 filings
10-Q
2024 Q1
BPMC
Blueprint Medicines Corp
Quarterly report
2 May 24
4:43pm
8-K
BPMC
Blueprint Medicines Corp
2 May 24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
7:09am
ARS
2023 FY
BPMC
Blueprint Medicines Corp
25 Apr 24
Annual report to shareholders
5:25pm
DEF 14A
BPMC
Blueprint Medicines Corp
Definitive proxy
25 Apr 24
5:24pm
8-K
BPMC
Blueprint Medicines Corp
25 Apr 24
Other Events
8:30am
8-K
bu774cd4
22 Feb 24
Other Events
8:20am
S-8
ego2zi
16 Feb 24
Registration of securities for employees
4:40pm
8-K
7h4vs
15 Feb 24
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
7:05am
8-K
tdh87e hf
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
a2gvdixcqo sk
26 Oct 23
Blueprint Medicines Reports Third Quarter 2023 Results
7:00am
8-K
ac84ci0 0ma0
25 Aug 23
Other Events
8:15am
8-K
lj92wenujfh6ofq9l6w
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
s7x53pl8zdl wjud
30 Jun 23
Other Events
6:03am
8-K
5d4m2 fxr8n40dj
27 Jun 23
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
hrx7sy5ssxr
25 May 23
Entry into a Material Definitive Agreement
4:32pm
8-K
9qoii46
22 May 23
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
4:53pm